178 related articles for article (PubMed ID: 27784733)
1. Comprehensive Analysis of Established Dyslipidemia-Associated Loci in the Diabetes Prevention Program.
Varga TV; Winters AH; Jablonski KA; Horton ES; Khare-Ranade P; Knowler WC; Marcovina SM; Renström F; Watson KE; Goldberg R; Florez JC; Pollin TI; Franks PW
Circ Cardiovasc Genet; 2016 Dec; 9(6):495-503. PubMed ID: 27784733
[TBL] [Abstract][Full Text] [Related]
2. Genetic modulation of lipid profiles following lifestyle modification or metformin treatment: the Diabetes Prevention Program.
Pollin TI; Isakova T; Jablonski KA; de Bakker PI; Taylor A; McAteer J; Pan Q; Horton ES; Delahanty LM; Altshuler D; Shuldiner AR; Goldberg RB; Florez JC; Franks PW;
PLoS Genet; 2012; 8(8):e1002895. PubMed ID: 22951888
[TBL] [Abstract][Full Text] [Related]
3. Sex-Specific Parental Effects on Offspring Lipid Levels.
Predazzi IM; Sobota RS; Sanna S; Bush WS; Bartlett J; Lilley JS; Linton MF; Schlessinger D; Cucca F; Fazio S; Williams SM
J Am Heart Assoc; 2015 Jun; 4(7):. PubMed ID: 26126546
[TBL] [Abstract][Full Text] [Related]
4. Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program.
Goldberg RB; Mather K
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2077-90. PubMed ID: 22895669
[TBL] [Abstract][Full Text] [Related]
5. Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program.
Goldberg RB; Temprosa M; Mele L; Orchard T; Mather K; Bray G; Horton E; Kitabchi A; Krakoff J; Marcovina S; Perreault L; White N;
Metabolism; 2016 May; 65(5):764-775. PubMed ID: 27085783
[TBL] [Abstract][Full Text] [Related]
6. Interactions of Lipid Genetic Risk Scores With Estimates of Metabolic Health in a Danish Population.
Justesen JM; Allin KH; Sandholt CH; Borglykke A; Krarup NT; Grarup N; Linneberg A; Jørgensen T; Hansen T; Pedersen O
Circ Cardiovasc Genet; 2015 Jun; 8(3):465-72. PubMed ID: 25714099
[TBL] [Abstract][Full Text] [Related]
7. Genetic Predisposition to Dyslipidemia and Risk of Preeclampsia.
Spracklen CN; Saftlas AF; Triche EW; Bjonnes A; Keating B; Saxena R; Breheny PJ; Dewan AT; Robinson JG; Hoh J; Ryckman KK
Am J Hypertens; 2015 Jul; 28(7):915-23. PubMed ID: 25523295
[TBL] [Abstract][Full Text] [Related]
8. Associations of genetic variants for adult lipid levels with lipid levels in children. The Generation R Study.
Latsuzbaia A; Jaddoe VWV; Hofman A; Franco OH; Felix JF
J Lipid Res; 2016 Dec; 57(12):2185-2192. PubMed ID: 27777320
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Betteridge DJ; Vergès B
Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
[TBL] [Abstract][Full Text] [Related]
10. Genetic determinants of blood lipids and cerebral small vessel disease: role of high-density lipoprotein cholesterol.
Georgakis MK; Malik R; Anderson CD; Parhofer KG; Hopewell JC; Dichgans M
Brain; 2020 Feb; 143(2):597-610. PubMed ID: 31968102
[TBL] [Abstract][Full Text] [Related]
11. Weight gain prevention buffers the impact of CETP rs3764261 on high density lipoprotein cholesterol in young adulthood: The Study of Novel Approaches to Weight Gain Prevention (SNAP).
McCaffery JM; Ordovas JM; Huggins GS; Lai CQ; Espeland MA; Tate DF; Wing RR
Nutr Metab Cardiovasc Dis; 2018 Aug; 28(8):816-821. PubMed ID: 29699816
[TBL] [Abstract][Full Text] [Related]
12. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
[TBL] [Abstract][Full Text] [Related]
13. Do genetic modifiers of high-density lipoprotein cholesterol and triglyceride levels also modify their response to a lifestyle intervention in the setting of obesity and type-2 diabetes mellitus?: The Action for Health in Diabetes (Look AHEAD) study.
Huggins GS; Papandonatos GD; Erar B; Belalcazar LM; Brautbar A; Ballantyne C; Kitabchi AE; Wagenknecht LE; Knowler WC; Pownall HJ; Wing RR; Peter I; McCaffery JM;
Circ Cardiovasc Genet; 2013 Aug; 6(4):391-9. PubMed ID: 23861364
[TBL] [Abstract][Full Text] [Related]
14. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
15. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
[TBL] [Abstract][Full Text] [Related]
16. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
[TBL] [Abstract][Full Text] [Related]
17. Genetic loci for serum lipid fractions and intracerebral hemorrhage.
Akoudad S; Ikram MA; Portegies ML; Adams HH; Bos D; Hofman A; Koudstaal PJ; Uitterlinden AG; van der Lugt A; van Duijn CM; Vernooij MW
Atherosclerosis; 2016 Mar; 246():287-92. PubMed ID: 26820804
[TBL] [Abstract][Full Text] [Related]
18. Effect of Fructose on Established Lipid Targets: A Systematic Review and Meta-Analysis of Controlled Feeding Trials.
Chiavaroli L; de Souza RJ; Ha V; Cozma AI; Mirrahimi A; Wang DD; Yu M; Carleton AJ; Di Buono M; Jenkins AL; Leiter LA; Wolever TM; Beyene J; Kendall CW; Jenkins DJ; Sievenpiper JL
J Am Heart Assoc; 2015 Sep; 4(9):e001700. PubMed ID: 26358358
[TBL] [Abstract][Full Text] [Related]
19. Causal Effects of Intensive Lifestyle and Metformin Interventions on Cardiovascular Disease Risk Factors in Pre-Diabetic People: An Application of G-Estimation.
Salimi Y; Fotouhi A; Mohammad K; Mansournia N; Mansournia MA
Arch Iran Med; 2017 Jan; 20(1):55-59. PubMed ID: 28112533
[TBL] [Abstract][Full Text] [Related]
20. Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program.
Goldberg R; Temprosa M; Otvos J; Brunzell J; Marcovina S; Mather K; Arakaki R; Watson K; Horton E; Barrett-Connor E
J Clin Endocrinol Metab; 2013 Oct; 98(10):3989-98. PubMed ID: 23979954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
